{
    "organizations": [],
    "uuid": "48f67935c892ef0fe949f605f2f2f24e3d6b380d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-astrazeneca-presents-new-data-eval/brief-astrazeneca-presents-new-data-evaluating-safety-and-efficacy-of-farxiga-idUSFWN1R10T3",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Presents New Data Evaluating Safety And Efficacy Of Farxiga",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 19, 2018 / 4:23 PM / in 24 minutes BRIEF-Astrazeneca Presents New Data Evaluating Safety And Efficacy Of Farxiga Reuters Staff 1 Min Read March 19 (Reuters) - Astrazeneca Plc: * ASTRAZENECA PRESENTS NEW DATA EVALUATING SAFETY AND EFFICACY OF FARXIGA IN PATIENTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT * ASTRAZENECA - STUDY MET ITS PRIMARY AND SECONDARY EFFICACY ENDPOINTS * ASTRAZENECA - MEAN EGFR WAS DECREASED AT 24 WEEKS WITH DAPAGLIFLOZIN VERSUS PLACEBO IN STUDY * ASTRAZENECA - OVERALL, ADVERSE EVENTS OCCURRED IN 41.9% OF PATIENTS WITH DAPAGLIFLOZIN AND 47.8% WITH PLACEBO IN STUDY * ASTRAZENECA - AES RELATED TO STUDY TREATMENT BY INVESTIGATORS WERE REPORTED IN 10.6% OF PATIENTS WITH DAPAGLIFLOZIN AND 6.2% WITH PLACEBO * ASTRAZENECA - NO AES OF BONE FRACTURE OR AMPUTATION WERE REPORTED IN STUDY Source text for Eikon: Further company coverage:",
    "published": "2018-03-19T18:23:00.000+02:00",
    "crawled": "2018-03-19T18:35:48.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "present",
        "new",
        "data",
        "evaluating",
        "safety",
        "efficacy",
        "farxiga",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "astrazeneca",
        "plc",
        "astrazeneca",
        "present",
        "new",
        "data",
        "evaluating",
        "safety",
        "efficacy",
        "farxiga",
        "patient",
        "type",
        "diabetes",
        "moderate",
        "renal",
        "impairment",
        "astrazeneca",
        "study",
        "met",
        "primary",
        "secondary",
        "efficacy",
        "endpoint",
        "astrazeneca",
        "mean",
        "egfr",
        "decreased",
        "week",
        "dapagliflozin",
        "versus",
        "placebo",
        "study",
        "astrazeneca",
        "overall",
        "adverse",
        "event",
        "occurred",
        "patient",
        "dapagliflozin",
        "placebo",
        "study",
        "astrazeneca",
        "aes",
        "related",
        "study",
        "treatment",
        "investigator",
        "reported",
        "patient",
        "dapagliflozin",
        "placebo",
        "astrazeneca",
        "aes",
        "bone",
        "fracture",
        "amputation",
        "reported",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}